-
公开(公告)号：US6165464A
公开(公告)日：2000-12-26
申请号：US044197
申请日：1998-03-17
IPC分类号： A61K31/00 , A61K31/365 , A61K31/366 , A61K31/40 , A61K31/407 , A61K31/505 , A61K31/519 , A61K31/529 , A61K31/70 , A61K31/7008 , A61K33/24 , A61K38/00 , A61K38/21 , A61K39/395 , A61K45/00 , A61K47/48 , A61P35/00 , A61P43/00 , C07K1/22 , C07K14/00 , C07K14/485 , C07K14/495 , C07K14/52 , C07K14/525 , C07K14/54 , C07K14/545 , C07K14/55 , C07K14/555 , C07K14/57 , C07K14/705 , C07K14/715 , C07K16/00 , C07K16/22 , C07K16/28 , C07K16/30 , C07K16/32 , C07K19/00 , C12N5/10 , C12N15/02 , C12P21/08 , C12R1/91 , G01N33/573 , G01N33/574 , G01N33/577 , C12N5/12
CPC分类号： C07K16/32 , A61K38/00 , A61K39/395 , A61K47/6843 , A61K47/6849 , A61K2039/505 , C07K16/22 , C07K16/30 , C07K16/3015 , C07K2317/73 , A61K2300/00 , A61K38/217 , A61K38/2013 , A61K38/2006 , A61K38/191
摘要： A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
-
公开(公告)号：US6051397A
公开(公告)日：2000-04-18
申请号：US153397
申请日：1993-11-16
IPC分类号： A61K38/00 , C07K14/705 , C12N15/12 , C12N5/10 , C12N15/62
CPC分类号： A61K51/103 , C07K14/705 , C07K16/2863 , A61K38/00 , C07K2317/34 , C07K2319/00 , C12N2799/027
摘要： The present invention relates to the novel family of receptor tyrosine kinases, herein referred to as MCK-10, to nucleotide sequences and expression vectors encoding MCK-10, and to methods of inhibiting MCK-10 activity. The invention relates to differentially spliced isoforms of MCK-10 and to other members of the MCK-10 receptor tyrosine kinase family. Genetically engineered host cells that express MCK-10 may be used to evaluate and screen drugs involved in MCK-10 activation and regulation. The invention relates to the use of such drugs, in the treatment of disorders, including cancer, by modulating the activity of MCK-10.
摘要翻译： 本发明涉及受体酪氨酸激酶（本文中称为MCK-10）与编码MCK-10的核苷酸序列和表达载体的新家族，以及抑制MCK-10活性的方法。 本发明涉及MCK-10和MCK-10受体酪氨酸激酶家族的其他成员的差异拼接同种型。 表达MCK-10的基因工程宿主细胞可用于评估和筛选涉及MCK-10激活和调节的药物。 本发明涉及通过调节MCK-10的活性来治疗疾病，包括癌症中的这些药物的用途。
-
公开(公告)号：US6015567A
公开(公告)日：2000-01-18
申请号：US422108
申请日：1995-04-14
摘要： A method of treating a human patient via active immunotherapy comprising administrating an effective amount of extracellular portion of human HER2 receptor to the patient wherein the method provokes a cell-mediated immune response to HER2 receptor in the patient treated therewith.
摘要翻译： 一种通过主动免疫疗法治疗人类患者的方法，其包括向患者施用有效量的人HER2受体的细胞外部分，其中所述方法在用其治疗的患者中引发对HER2受体的细胞介导的免疫应答。
-
公开(公告)号：US5945523A
公开(公告)日：1999-08-31
申请号：US732870
申请日：1996-10-15
申请人： Axel Ullrich , Klaus Seedorf
发明人： Axel Ullrich , Klaus Seedorf
CPC分类号： C07K14/47
摘要： The present invention relates to TKA-1 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for TKA-1 related diseases or conditions characterized by an abnormal interaction between a TKA-1 polypeptide and a TKA-1 binding partner.
摘要翻译： 本发明涉及TKA-1多肽，编码此类多肽的核酸，含有此类核酸的细胞，组织和动物，对此类多肽的抗体，利用此类多肽的测定法，以及与上述所有相关的方法。 提供TKA-1相关疾病或TKA-1多肽与TKA-1结合配偶体异常相互作用特征的治疗，诊断和筛选方法。
-
公开(公告)号：US5922842A
公开(公告)日：1999-07-13
申请号：US666067
申请日：1996-06-13
申请人： Klaus Seedorf , Axel Ullrich
发明人： Klaus Seedorf , Axel Ullrich
IPC分类号： C07K14/47 , C07K14/435 , C12N15/09
CPC分类号： C07K14/47
摘要： The present invention relates to TKA-1 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for TKA-1 related diseases or conditions characterized by an abnormal interaction between a TKA-1 polypeptide and a TKA-1 binding partner.
摘要翻译： 本发明涉及TKA-1多肽，编码此类多肽的核酸，含有此类核酸的细胞，组织和动物，对此类多肽的抗体，利用此类多肽的测定法，以及与上述所有相关的方法。 提供TKA-1相关疾病或TKA-1多肽与TKA-1结合配偶体异常相互作用特征的治疗，诊断和筛选方法。
-
公开(公告)号：US5856111A
公开(公告)日：1999-01-05
申请号：US751900
申请日：1996-11-18
CPC分类号： G01N33/74 , C07K14/72 , C12N9/16 , C12Q1/42 , G01N2333/62 , G01N2333/72 , G01N2333/9121 , G01N2500/10
摘要： The present invention relates to cell lines useful for the screening and identification of compounds that by modulating phosphotyrosine phosphatase activity, modulate insulin receptor type tyrosine kinase mediated signal transduction. Genetically engineered cells expressing IR in culture overcome the effect of insulin on morphology and adhesion when they are also coexpressing RPTP.alpha. or RPTP.epsilon.. Such engineered cell lines may be used to screen and identify non-toxic compounds that could elicit or modulate insulin signal transduction even in the absence of insulin.
摘要翻译： 本发明涉及可用于筛选和鉴定通过调节磷酸酪氨酸磷酸酶活性，调节胰岛素受体型酪氨酸激酶介导的信号转导的化合物的细胞系。 在培养物中表达IR的基因工程细胞克服了当它们共表达RPTPα或RPTPε时胰岛素对形态和粘附的作用。 这样的工程细胞系可用于筛选和鉴定甚至在不存在胰岛素时也可引发或调节胰岛素信号转导的无毒化合物。
-
公开(公告)号：US5772997A
公开(公告)日：1998-06-30
申请号：US447478
申请日：1995-05-23
IPC分类号： A61K31/00 , A61K31/365 , A61K31/366 , A61K31/40 , A61K31/407 , A61K31/505 , A61K31/519 , A61K31/529 , A61K31/70 , A61K31/7008 , A61K33/24 , A61K38/00 , A61K38/21 , A61K39/395 , A61K45/00 , A61K47/48 , A61P35/00 , A61P43/00 , C07K1/22 , C07K14/00 , C07K14/485 , C07K14/495 , C07K14/52 , C07K14/525 , C07K14/54 , C07K14/545 , C07K14/55 , C07K14/555 , C07K14/57 , C07K14/705 , C07K14/715 , C07K16/00 , C07K16/22 , C07K16/28 , C07K16/30 , C07K16/32 , C07K19/00 , C12N5/10 , C12N15/02 , C12P21/08 , C12R1/91 , G01N33/573 , G01N33/574 , G01N33/577 , C07K16/46
CPC分类号： C07K16/32 , A61K39/395 , A61K47/48538 , A61K47/48561 , C07K16/22 , C07K16/30 , C07K16/3015 , A61K2039/505 , A61K38/00 , C07K2317/73
摘要： A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treatment tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors.
摘要翻译： 公开了通过用抑制生长因子受体功能的抗体处理细胞来抑制过表达生长因子受体或生长因子的肿瘤细胞生长的方法。 还公开了用抑制生长因子受体功能的抗体和细胞毒性因子如肿瘤坏死因子治疗肿瘤细胞的方法。 通过抑制生长因子受体功能，肿瘤细胞对细胞毒性因子的敏感性更高。
-
58.发明授权
公开(公告)号：US5700822A
公开(公告)日：1997-12-23
申请号：US457047
申请日：1995-06-01
申请人： Klaus Peter Hirth , Donna Pruess Schwartz , Elaina Mann , Laura Kay Shawver , Gyorgi Keri , Istvan Szekely , Tamas Bajor , Janis Haimichael , Laszlo Orfi , Alex Levitzki , Aviv Gazit , Axel Ullrich , Reiner Lammers , Fairooz F. Kabbinavar , Dennis Slamon , Peng Cho Tang
发明人： Klaus Peter Hirth , Donna Pruess Schwartz , Elaina Mann , Laura Kay Shawver , Gyorgi Keri , Istvan Szekely , Tamas Bajor , Janis Haimichael , Laszlo Orfi , Alex Levitzki , Aviv Gazit , Axel Ullrich , Reiner Lammers , Fairooz F. Kabbinavar , Dennis Slamon , Peng Cho Tang
IPC分类号： A61K9/00 , A61K31/165 , A61K31/167 , A61K31/275 , A61K31/277 , A61K31/38 , A61K31/40 , A61K31/415 , A61K31/42 , A61K31/421 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/495 , A61K31/505 , A61K31/535 , A61K45/06 , A61K47/10 , A61K47/26 , C07C255/23 , C07D231/38 , C07D239/91 , C07D241/38 , C07D241/42 , C07D487/04 , C07D498/04 , G01N33/50
CPC分类号： C07D231/38 , A61K31/165 , A61K31/167 , A61K31/275 , A61K31/277 , A61K31/38 , A61K31/40 , A61K31/415 , A61K31/42 , A61K31/421 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/495 , A61K31/505 , A61K31/535 , A61K45/06 , A61K47/10 , A61K47/26 , A61K9/0019 , C07C255/23 , C07D239/91 , C07D241/38 , C07D241/42 , C07D487/04 , G01N33/5011 , Y10S977/904 , Y10S977/911 , Y10S977/912 , Y10S977/915
摘要： The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.
摘要翻译： 本发明涉及可以抑制血小板衍生生长因子受体（PDGF-R）活性的化合物，优选地，这些化合物也抑制PDGF-R超家族的其他成员的活性，并且对PDGF-R超家族的成员是选择性的。 PDGF-R超家族包括PDGF-R和PDGF-R相关的激酶Flt和KDR。 特征化合物在细胞培养物中是有活性的，以降低PDGF-R，优选一种或多种PDGF-R相关激酶的活性。 以下描述特征化合物A10（参见图1a）及其抑制体内肿瘤细胞生长的能力的实例。 使用本申请作为指导，可以获得能够抑制PDGF-R，优选Flt和/或KDR的其它化合物。 这些化合物优选用于治疗患有以不适当的PDGF-R活性为特征的细胞增殖性疾病的患者。
-
公开(公告)号：US5677171A
公开(公告)日：1997-10-14
申请号：US286303
申请日：1994-08-05
IPC分类号： A61K31/00 , A61K31/365 , A61K31/366 , A61K31/40 , A61K31/407 , A61K31/505 , A61K31/519 , A61K31/529 , A61K31/70 , A61K31/7008 , A61K33/24 , A61K38/00 , A61K38/21 , A61K39/395 , A61K45/00 , A61K47/48 , A61P35/00 , A61P43/00 , C07K1/22 , C07K14/00 , C07K14/485 , C07K14/495 , C07K14/52 , C07K14/525 , C07K14/54 , C07K14/545 , C07K14/55 , C07K14/555 , C07K14/57 , C07K14/705 , C07K14/715 , C07K16/00 , C07K16/22 , C07K16/28 , C07K16/30 , C07K16/32 , C07K19/00 , C12N5/10 , C12N15/02 , C12P21/08 , C12R1/91 , G01N33/573 , G01N33/574 , G01N33/577
CPC分类号： C07K16/32 , A61K39/395 , A61K47/48538 , A61K47/48561 , C07K16/22 , C07K16/30 , C07K16/3015 , A61K2039/505 , A61K38/00 , C07K2317/73
摘要： Monoclonal antibodies which bind to the extracellular domain of the HER2 receptor and inhibit growth of SK-BR-3 breast tumor cells, which overexpress HER2, are disclosed. The monoclonal antibodies can be used for in vitro assays for detecting a tumor characterized by amplified expression of HER2.
摘要翻译： 公开了结合HER2受体细胞外结构域并抑制过表达HER2的SK-BR-3乳腺肿瘤细胞生长的单克隆抗体。 单克隆抗体可用于体外检测用于检测HER2扩增表达特征的肿瘤。
-
公开(公告)号：US5589375A
公开(公告)日：1996-12-31
申请号：US18129
申请日：1993-02-16
申请人： Axel Ullrich , Wolfgang Vogel
发明人： Axel Ullrich , Wolfgang Vogel
IPC分类号： C12N15/09 , A61K38/00 , A61K38/45 , A61P43/00 , C07H21/04 , C07K14/47 , C07K14/705 , C07K16/40 , C12N9/16 , C12N15/55 , C12P21/08 , C12Q1/34 , C12Q1/68 , G01N33/573 , C12N5/06
CPC分类号： C07K14/705 , C12N9/16 , G01N33/573 , A61K38/00 , C07K2319/00
摘要： A novel protein tyrosine phosphatase is the protein designated PTP 1D. The PTP 1D protein may be produced by recombinant means, for example using a nucleic acid construct encoding the protein as provided herein. Also disclosed is an antibody specific for an epitope of PTP 1D, protein. Methods for identifying compounds which bind to a PTP 1D protein and inhibit or stimulate its enzymatic activity, pharmaceutical compositions comprising PTP 1D, and methods for treating a disease associated with PTP 1D protein using such compositions, are provided.
-
-
-
-
-
-
-
-
-
搜索结果
112 条记录 (耗时 0.042 秒)
